Targeting the PI3K/AKT pathway has been investigated with a range of PI3K inhibitors which can be isoform-specific inhibitors, pan class I inhibitors (e.g. pictilisib, GDC-0941) or dual PI3K/mTOR inhibitors (e.g. dactolisib, NVP-BEZ235), and promising anti-cancer efficacy has been reported in pre-clinical models [10–16]. Here, PIK3CA is linked to cancer.